Evidence map›Paper›PMID 37605150›Full record

ArticleHealth and quality of life outcomes2023

Determinants of health-related quality of life in people with Human Immunodeficiency Virus, failing first-line treatment in Africa.

Tamlyn A Rautenberg, Shu Kay Ng, Gavin George, Mahomed-Yunus S Moosa, Suzanne M McCluskey, Rebecca F Gilbert, Selvan Pillay, Isaac Aturinda, Kevin L Ard, Winnie R Muyindike and 11 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02787499 (Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02787499 nacompletednot on this map

Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa

TypeinterventionalSponsorMassachusetts General HospitalRan2016 to 2020Enrolled840ConditionsHIV, AIDSArmsHIV-1 RNA Resistance Testing
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Tamlyn A RautenbergSchool of Medicine and Dentistry, Centre for Applied Health Economics, Griffith University, Australia (Sir Samuel Griffith Centre N78 Room 2.34), Nathan campus, QLD, 4111, Australia. t.rautenberg@griffith.edu.au.
Shu Kay NgSchool of Medicine and Dentistry, Centre for Applied Health Economics, Griffith University, Australia (Sir Samuel Griffith Centre N78 Room 2.34), Nathan campus, QLD, 4111, Australia.
Gavin GeorgeHealth Economics and HIV Research Division, University of KwaZulu-Natal, Durban, South Africa.
Mahomed-Yunus S MoosaCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Suzanne M McCluskeyDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Rebecca F GilbertDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Selvan PillayCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Isaac AturindaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Kevin L ArdDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Winnie R MuyindikeFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Nicholas MusinguziFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Godfrey MasetteFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Melendhran PillayNational Health Laboratory Service, Durban, South Africa.
Pravi MoodleyDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Jaysingh BrijkumarCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Rajesh T GandhiDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Brent JohnsonDepartment of Biostatistics and Computation Biology, University of Rochester, Rochester, NY, USA.
Henry SunpathCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Mwebesa B BwanaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Vincent C MarconiDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Mark J SiednerCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Mbarara University of Science and Technology · UGUniversity of KwaZulu-Natal · ZAMassachusetts General Hospital · USMenzies School of Health Research · AUNational Health Laboratory Service · ZAAfrica Health Research Institute · ZAGeorgia Department of Public Health · USHarvard University · USUniversity of Rochester · US

Funding

Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trialR01AI124718 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MUYINDIKE, WINNIE, SIEDNER, MARK J · 2016 to 2020
$3.0M
NIAID NIH HHS R01 AI124718NIH HHS NIH R01 AI124718
6 · The paper itself

Abstract

backgroundAntiretroviral treatment improves health related quality of life (HRQoL) of people with human immunodeficiency virus (PWH). However, one third initiating first-line treatment experience virological failure and the determinants of HRQoL in this key population are unknown. Our study aims to identify determinants of among PWH failing antiretroviral treatment in sub-Saharan Africa.

methodsWe analysed data from a cohort of PWH having virological failure (> 1,000 copies/mL) on first-line ART in South Africa and Uganda. We measured HRQoL using the EuroQOL EQ-5D-3L and used a two-part regression model to obtain by-country analyses for South Africa and Uganda. The first part identifies risk factors that were associated with the likelihood of participants reporting perfect health (utility = 1) versus non-perfect health (utility < 1). The second part identifies risk factors that were associated with the EQ-5 L-3L utility scores for participants reporting non-perfect health. We performed sensitivity analyses to compare the results between the two-part model using tobit models and ordinary least squares regression.

resultsIn both countries, males were more likely to report perfect health and participants with at least one comorbidity were less likely to report perfect health. In South Africa, participants with side effects and in Uganda those with opportunistic infections were also less likely to report perfect health. In Uganda, participants with 100% ART adherence were more likely to report perfect health. In South Africa, high HIV viral load, experiencing ART side effects, and the presence of opportunistic infections were each associated with lower HRQoL, whereas participants with 100% ART adherence reported higher HRQoL. In Uganda participants with lower CD4 count had lower HRQoL.

conclusionMarkers of advanced disease (opportunistic infection, high viral load, low CD4), side effects, comorbidities and lack of ART adherence negatively impacted HRQoL for PWH experiencing virological failure.

trial registrationClinicalTrials.gov: NCT02787499.

Indexed as

HIV InfectionsOpportunistic InfectionsAnti-Retroviral AgentsHIVHumansMaleQuality of LifeSouth AfricaAnti-Retroviral AgentsEQ-5DHealth related quality-of-lifeHealth state utility valuesHIVTwo part regressionVirological failure

Identifiers

PMID37605150
PMCPMC10441724
OpenAlexW4386026324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.